证券代码：832982 证券简称：锦波生物 公告编号：2025-075 山西锦波生物医药股份有限公司 关于向特定对象发行股票摊薄即期回报、采取填补措施 及相关承诺的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据《国务院办公厅关于进一步加强资本市场中小投资者合法权益保护工作 的意见》（国办发[2013]110 号）以及中国证券监督管理委员会（以下简称"中 国证监会"）发布的《关于首发及再融资、重大资产重组摊薄即期回报有关事项 的指导意见》（证监会公告[2015]31 号）等有关规定，为保障中小投资者知情权， 维护中小投资者利益，山西锦波生物医药股份有限公司（以下简称"公司"或"锦 波生物"）就本次向特定对象发行股票对即期回报摊薄的影响进行了分析，并提 出了具体的填补回报措施，相关主体对公司填补回报措施能够得到切实履行作出 了承诺。具体内容如下： 一、本次向特定对象发行股票摊薄即期回报对公司主要财务指标的影响 （一）测算的主要假设条件 2、假设本次向特定对象发行股票募集资金总额为 200,000 ...

山西锦波生物医药股份有限公司 前次募集资金使用情况鉴证报告 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn ■ 门 门 门 ■ 门 门 门 [] □ 口 E 门 门 □ ■ ■ L 口 口 ■ ■ ■ ■ ■ ■ ■ 口 ■ ■ ■ n E | 目 | 景 | | --- | --- | | 一、前次募集资金使用情况鉴证报告 | | | 二、山西锦波生物医药股份有限公司关于前次募集资金使用情 | | | 况的报告 | | | 三、事务所执业资质证明 | | 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-077 山西锦波生物医药股份有限公司 关于签署附条件生效的股份认购暨战略合作协议并构成关联交易的 公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、关联交易概述 （一）关联交易概述 山西锦波生物医药股份有限公司（以下简称"公司"）拟向养生堂有限公 司（以下简称"养生堂"）发行不超过 7,175,660 股（含本数）股票，占本次 发行前公司总股本的 6.24%，发行价格为 278.72 元/股，募集资金总额不超 过人民币 200,000 万元。未超过本次发行前公司总股本的 30%。本次发行对 象为养生堂，就本次向特定对象发行事项，养生堂于 2025 年 6 月 26 日与公 司签订了《山西锦波生物医药股份有限公司向特定对象发行股票之附条件生 效的股份认购暨战略合作协议》。养生堂以现金方式认购公司本次向特定对象 发行的股份。本次发行价格不低于定价基准日前 20 个交易日（不含定价基准 日）公司股票交易均价的 80%，定价基准日为公司第四 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-088 山西锦波生物医药股份有限公司 2025 年向特定对象发行股票 募集资金使用可行性分析报告 二〇二五年六月 单位：万元 项目名称 投资金额 占比 人源化胶原蛋白 FAST 数据库 与产品开发平台项目 115,000.00 57.50% 补充流动资金 85,000.00 42.50% 合计 200,000.00 100.00% 山西锦波生物医药股份有限公司 2025 年度向特定对象发行股票募集资金使用可行性分析报告 第二节 本次募集资金投资项目的必要性分析 一、积极响应我国大健康产业需求，弥补国内市场空缺 随着社会对健康需求的日益增长，以及临床医学对高效、安全治疗手段的迫 切需求，创新医疗器械和高端医疗产品的研发显得尤为重要。然而，国内在皮肤 肌肉修复、软骨修复、毛发增量及干眼症治疗等领域，现有的临床治疗方案仍存 在一定的局限性，尤其是高端医疗器械的自主研发能力相对较弱，众多高端产品 仍需依赖进口，导致国内市场存在较大的国产替代发展空间。公司采用先进的生 物合成技术，成功制备出重组人源化胶原蛋白，其不仅能够克服传统动物源胶原 蛋白的局限性，如 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-076 山西锦波生物医药股份有限公司 未来三年（2025-2027年）股东分红回报规划 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 为进一步规范和完善山西锦波生物医药股份有限公司（以下简称"公司"）利 润分配政策，建立科学、持续、稳定、透明的分红决策和监督机制，积极回报投资 者，根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司监管指 引第3号——上市公司现金分红》以及《山西锦波生物医药股份有限公司章程》（以 下简称"《公司章程》"）等相关文件的规定和要求，并结合公司盈利能力、经营 发展规划、股东回报及外部融资环境等因素，公司制定了《山西锦波生物医药股份 有限公司未来三年（2025-2027年）股东分红回报规划》（以下简称"本规划"）， 具体内容如下： 一、公司制定本规划考虑的因素 2、利润分配形式 公司采用现金、股票或者现金与股票相结合或者法律、法规允许的其他方式分 配利润。在公司当期的盈利规模、现金流状况、资金需求状况允 ...

锦波生物公告，养生堂有限公司计划通过定向发行的方式增持公司股份，增持比例达6.24%。本次股份 变动尚需2025年第二次临时股东会审议通过，并经过北京证券交易所审核和中国证监会注册同意后方可 实施。此外，久视管理咨询合伙企业通过协议转让，已增持锦波生物5%的股份。信息披露义务人承 诺，除本报告书所披露的持股信息外，没有通过其他方式增加或减少其在锦波生物中拥有的权益股份。 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-070 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、基本情况 本次工商变更完成后，公司注册资本由"捌仟捌佰伍拾壹万壹仟捌佰圆整" 变更为"壹亿壹仟伍佰零陆万伍仟叁佰肆拾圆整"，除以上变更外，《营业执照》 记载的其他工商登记事项未发生变更。 山西锦波生物医药股份有限公司 本次《公司章程》修订内容已在山西转型综合改革示范区管理委员会完成 备案。 关于完成工商变更登记及公司章程备案并取得营业执照的公告 三、备查文件 山西锦波生物医药股份有限公司（以下简称"公司"）于 2025 年 4 月 19 日 召开第四届董事会第八次会议、2025 年 5 月 21 日召开 2024 年年度股东会，审 议通过了《关于拟变更注册资本修订<公司章程>并办理工商变更登记的议案》， 具体内容详见于 2025 年 4 月 21 日在北京证券交易所指定信息披露平台 （https://www.bse.cn）披露的《关于拟修订〈公司章程〉公告》（公告编号： 2025- ...

Core Viewpoint - JINBO Biotech is the only company in China with three Class III certifications for injectable recombinant humanized collagen, leading the development of innovative medical materials and aiming to become a global leader in life materials [1][2]. Group 1: Product Development and Innovation - The company has successfully developed a full range of recombinant type III humanized collagen products, including freeze-dried fibers, solutions, and gels, establishing a comprehensive product system [2][3]. - JINBO Biotech's research has led to the first large-scale production of recombinant type III humanized collagen with a 164.88° triple helix structure, marking a significant breakthrough in the field [2][3]. - The company emphasizes the importance of eliminating immunogenicity and achieving large-scale production of collagen materials to meet safety and efficacy demands in medical applications [2][3]. Group 2: Research and Development Investment - In 2024, JINBO Biotech plans to invest 123 million yuan in R&D, an increase of 18.71% year-on-year, representing 8.52% of its revenue [4]. - The company is focusing on various types of humanized collagen projects, with some products already entering clinical trials [4][5]. Group 3: International Collaboration and Standards - JINBO Biotech collaborates with leading companies like L'Oréal to enhance global recognition of its technologies and promote international market penetration [5]. - The company has taken a leading role in establishing international standards for medical devices made from bioengineered materials, enhancing China's technological influence in this field [5]. Group 4: Technological Advancements and AI Integration - The company has established a FAST database for humanized collagen, significantly improving R&D efficiency through AI technology, reducing the time for data screening from one month to one day [6]. - JINBO Biotech integrates advanced technologies such as AlphaFold for protein structure prediction and has established a smart laboratory to ensure data reliability and enhance R&D capabilities [6].

Investment Rating - The report rates the investment outlook for the medical beauty regenerative anti-aging injection industry as "Positive" [5] Core Insights - The regenerative anti-aging injection agents are emerging materials that achieve facial rejuvenation through different mechanisms compared to hyaluronic acid and botulinum toxin [1] - The midstream of the regenerative anti-aging injection industry chain is identified as the segment with the highest added value, supported by regulatory compliance, technological innovation, and market demand [2] - Future trends in the industry include increased demand driven by an aging population, a shift towards non-surgical aesthetic procedures, and advancements in technology and materials that enhance product efficacy [3] Summary by Sections 1. Overview of the Medical Beauty Regenerative Anti-Aging Injection Industry - Medical beauty injection products are categorized into hyaluronic acid, botulinum toxin, and regenerative anti-aging materials, with the latter being newly introduced in the domestic market [11] - Regenerative anti-aging injections include subclasses such as microsphere regeneration, collagen, and PDRN, each with distinct mechanisms and benefits [12][13] 2. Industry Chain Analysis - The midstream segment is characterized by high added value, with companies leveraging compliance, innovation, and production capabilities to establish competitive barriers [2][29] - The upstream involves raw material suppliers, while the downstream focuses on the distribution to end consumers through various channels [26] 3. Regulatory and Policy Environment - The industry is regulated by key agencies including the National Health Commission and the National Medical Products Administration, ensuring compliance across all stages from development to sales [43][46] 4. Market Size and Growth Potential - The market for medical beauty injections in China is projected to grow from 21.2 billion RMB in 2023 to 65.3 billion RMB by 2028, with a CAGR of 25.3% [17] - The regenerative anti-aging segment is expected to see a significant increase, with its market share rising from 3% in 2019 to an estimated 31% by 2028 [20] 5. Investment Recommendations - Companies with a comprehensive industry chain layout and a strong product portfolio, such as Jinbo Biological and East China Pharmaceutical, are highlighted as having strong growth potential and investment value [3]

Summary of Key Points Core Viewpoint - As of June 10, the total margin financing and securities lending balance on the Beijing Stock Exchange (BSE) was 5.535 billion yuan, a decrease of 38.81 million yuan from the previous trading day, indicating a slight decline in market activity [1]. Financing and Margin Data - The margin balance was 5.534 billion yuan, down by 38.83 million yuan, while the securities lending balance increased to 1.0842 million yuan, up by 15,000 yuan [1]. - The stocks with the highest margin balances included Jinbo Biological (365 million yuan), Airon Software (154 million yuan), and Better Energy (143 million yuan), with an average margin balance to market capitalization ratio of 1.11% [1]. Net Buying and Selling Trends - On June 10, 96 stocks experienced net margin buying, with 40 stocks having net buying amounts exceeding 1 million yuan. Shengye Electric led with a net buying amount of 15.4692 million yuan, followed by Thunder Technology and Jinbo Biological with 12.4114 million yuan and 8.792 million yuan, respectively [1]. - The stocks with the highest net selling amounts included Shuguang Digital Innovation, Air China Ocean, and Deyuan Pharmaceutical, with net selling amounts of 11.0707 million yuan, 9.7653 million yuan, and 9.6206 million yuan, respectively [1]. Industry Performance - The industries with the most stocks experiencing net buying over 1 million yuan were machinery equipment, electric power equipment, and basic chemicals, with 11, 7, and 5 stocks respectively [2]. - On average, stocks with net buying over 1 million yuan rose by 7.61%, with notable increases from Jiaoda Iron Transportation (262.09%), Huaguang Source Sea (26.88%), and Qiule Seed Industry (11.99%) [2]. Trading Activity - The weighted average turnover rate for stocks with net buying over 1 million yuan was 8.52%, with Jiaoda Iron Transportation, Night Light Ming, and Huaguang Source Sea having turnover rates of 72.03%, 42.37%, and 41.29%, respectively [2]. - The average daily turnover rate for BSE stocks on June 10 was 7.11% [2]. Notable Stocks and Changes - Stocks with the largest increases in margin balances included Shengye Electric (increase of 15.4692 million yuan), Thunder Technology (increase of 12.4114 million yuan), and Jinbo Biological (increase of 8.792 million yuan) [2][3]. - The stock performance varied, with some stocks experiencing significant declines, such as Road Bridge Information (-12.94%) and Qifeng Precision (-8.04%) [2][3].